(HealthDay News) — For individuals with type 1 diabetes, long-term use of continuous subcutaneous insulin infusion (insulin pump therapy) is associated with reduced cardiovascular (CV) and all-cause mortality, according to a study published in The BMJ.
Isabelle Steineck, MD, from the Aarhus University Hospital in Denmark, and colleagues examined the long-term effects of insulin pump therapy on cardiovascular diseases (CVDs) and mortality.
Data were included for 18,168 people with type 1 diabetes, of whom 2,441 used insulin pump therapy and 15,727 used multiple daily insulin injections. Patients were followed for a mean of 6.8 years, with 114,135 person-years.
Compared with multiple daily injections, insulin pump therapy led to adjusted hazard ratios that were significantly lower for fatal coronary heart disease (CHD; 0.55), fatal CVD (CHD or stroke; 0.58), and all-cause mortality (0.73).
For fatal or nonfatal CHD and fatal or nonfatal CVD, hazard ratios were lower, but not significantly so. Per 1,000 person-years, the unadjusted differences were 3.0 events of fatal CHD, 3.3 events of fatal CVD and 5.7 events for all-cause mortality.
The results of subgroup analyses were similar when lower BMI and previous CVDs were excluded.
“Among people with type 1 diabetes, use of insulin pump therapy is associated with lower cardiovascular mortality than treatment with multiple daily insulin injections,” the researchers wrote.
One author disclosed receiving lecture fees from Sanofi and Novo Nordisk.